Home >  Registry
     
 
 Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Anemia

  • A Study of Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Predialysis Patients Not Treated With ESA.
    Not yet recruiting


  • A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.
    Not yet recruiting


  • A Study of Once Monthly Intravenous or Subcutaneous Mircera in Patients With Chronic Kidney Disease on Hemodialysis.
    Not yet recruiting


  • A Study of Intravenous Mircera for the Treatment of Anemia in Pediatric Patients on Hemodialysis.
    Not yet recruiting


  • CARISMA Study: A Study of Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.
    Recruiting


  • A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Patients With Chronic Kidney Disease.
    Recruiting


  • LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
    Recruiting


  • A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.
    Recruiting


  • A Study of Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia.
    Recruiting


  • MIRACLE Study: A Study Of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.
    Recruiting


  • A Study of Intravenous Mircera for the Correction of Anemia in Dialysis Patients.
    Recruiting


  • A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease Not Treated With ESA or on Dialysis.
    Recruiting


  • A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.
    Recruiting


  • A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
    Recruiting


  • A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.
    Recruiting


  • A Study of Subcutaneous Mircera, Versus no ESA Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant.
    Recruiting


  • A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia.
    Recruiting


  • A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Patients.
    Recruiting


  • A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for the Maintenance Treatment of Anemia in Kidney Transplant Recipients.
    Recruiting


  • A Study of Intravenous Mircera for the Maintenance Treatment of Hemodialysis Patients With Chronic Renal Anemia
    Recruiting


  • STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients
    Recruiting


  • A Study of Subcutaneous Mircera For The Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
    Recruiting


  • A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.
    Recruiting


  • A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not on Dialysis.
    Recruiting


  • A Study of Intravenous Mircera in Patients With Chronic Renal Anemia who are on Dialysis.
    Recruiting


  • A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia
    Recruiting


  • A Study Comparing Mircera and Epoetin Beta for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.
    No longer recruiting


  • A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
    No longer recruiting


  • A Study of Subcutaneous Mircera for the Maintenance Treatment of Pre-Dialysis Patients With Chronic Renal Anemia.
    No longer recruiting


  • A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
    No longer recruiting


  • A Study of NeoRecormon (Epoetin Beta) in Patients With Solid Tumors or Hematologic Malignancies
    No longer recruiting


  • A Study of Mircera in the Long Term Treatment of Patients With Renal Anemia.
    No longer recruiting


  • A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy.
    No longer recruiting


  • A Study of NeoRecormon (Epoetin Beta) in Patients With End Stage Renal Disease.
    No longer recruiting


  • A Study of NeoRecormon in Patients With Chronic Kidney Disease.
    No longer recruiting


  • A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
    No longer recruiting


  • A Study of Mircera in Anemic Patients With Multiple Myeloma
    Completed


  • COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.
    Completed


  • A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Metastatic Breast Cancer
    Completed


  • A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Solid Tumors
    Completed


  • A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Hematologic Malignancies
    Completed


  • A Study of NeoRecormon (Epoetin Beta) in Patients With Lymphoid Malignancies
    Completed


  • A Study of Different Methods of Administration of NeoRecormon (Epoetin Beta) in Patients With Renal Anemia
    Completed


  • A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors
    Completed


  • A Study of NeoRecormon (Epoetin Beta) for Treatment of Anemia in Patients With Hematologic Malignancies.
    Completed


  • A Study of NeoRecormon (Epoetin Beta) for Prevention and Treatment of Anemia in Patients With Solid Tumors Receiving Platinum-Based Chemotherapy Prone to Induce Anemia
    Completed


  • A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy
    Completed


  • NADIR Study: A Study of Neorecormon (Epoetin Beta)in Anemic Patients With Diabetes and Chronic Renal Failure Who Are Not on Dialysis.
    Completed


  • A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.
    Completed


  • A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
    Completed


  • A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Solid Tumors
    Completed


  • A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Breast Cancer Undergoing Chemotherapy
    Completed


  • A Study of NeoRecormon (Epoetin Beta) in Patients With Renal Anemia
    Completed


  • A Study to Evaluate NeoRecormon (Epoetin Beta) in Anemic Patients With Solid Tumors Receiving Chemotherapy
    Completed


  • A Study of NeoRecormon (Epoetin Beta) in Patients With Solid Tumors or Hematologic Malignancies
    Completed


  • A Study of NeoRecormon (Epoetin Beta) in Patients With Refractory Anemia
    Completed


  • A Study of NeoRecormon (Epoetin Beta) in Predialysis Patients With Renal Anemia
    Completed


  • A Study of NeoRecormon (Epoetin Beta) in Patients With Solid Tumors
    Completed


  • A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia
    Completed


  • (BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer
    Completed


  • (ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy
    Completed


  • A Study of NeoRecormon (Epoetin Beta) in the Treatment of Patients on Hemodialysis
    Completed


  • (MARCH Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Advanced Cervical Cancer
    Completed


  • A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia
    Completed


  • A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.
    Completed


  • A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.
    Completed


  • A Study of Mircera in Patients With Non-Hodgkin's Lymphoma and Anemia.
    Completed


  • A Study of Mircera for the Treatment of Anemia in Dialysis Patients
    Completed


  • A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
    Completed


  • A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
    Completed


  • A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.
    Completed


  • A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
    Completed


  • A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients
    Completed


  • A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
    Terminated


  • A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Hematologic Malignancies.
    Terminated


  • A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.
    Terminated


  • A Study of NeoRecormon (Epoetin Beta) in Patients With Renal Anemia.
    Terminated


  • A Study of Once Weekly Versus Thrice Weekly NeoRecormon (Epoetin Beta) Therapy in Anemic Patients With Metastatic Solid Tumors Receiving Chemotherapy.
    Terminated


  • A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.
    Terminated


    		•

    © 1996-2008 F.Hoffmann-La Roche Ltd See our legal Statement